Form 4: Heron Therapeutics EVP Converts RSUs
Insider Transaction Report
Heron Therapeutics' EVP, William P. Forbes, converted 3,874 restricted stock units into common stock, increasing his direct beneficial ownership.
Summary
- William P. Forbes, EVP, Chief Development Officer of Heron Therapeutics, Inc. (HRTX), converted 3,874 restricted stock units (RSUs) into common stock.
- The transaction occurred on October 19, 2025.
- Following this transaction, Forbes directly beneficially owns 154,509 shares of common stock.
- He also directly beneficially owns 34,869 restricted stock units.
- Each restricted stock unit represents a contingent right to receive one share of common stock.
- The restricted stock units vest in 16 equal quarterly installments, beginning one quarter after January 19, 2024.
Sentiment
Score: 6
Explanation: The filing reports a routine insider transaction involving the vesting and conversion of restricted stock units, which is a neutral event. The executive's continued ownership of shares and RSUs is generally positive as it aligns interests with shareholders.
Positives
- Conversion of restricted stock units into common stock indicates a vesting event, which is a standard part of executive compensation.
- The executive's continued beneficial ownership of a significant number of shares (154,509 common stock) and RSUs (34,869) aligns management's interests with shareholders.
Future Outlook
No forward-looking statements or guidance are provided in this insider transaction report.
Industry Context
This is a routine insider transaction report and does not contain information related to broader industry trends or competitors.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | William P. Forbes, EVP, Chief Development Officer, granted a Power of Attorney to Kathryn Lester and Melissa Jarel to handle SEC filings (Forms 3, 4, 5, 13D, 13G, 144) and EDGAR system administration on his behalf. | 09/04/2025 | Streamlines compliance for insider reporting requirements, ensuring timely and accurate filings by authorized personnel. |
Stakeholder Impact
- Shareholders: Increased alignment of executive's interests with shareholders through continued stock ownership.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Grant date for restricted stock units, with vesting beginning one quarter after this date. |
| 09/04/2025 | Date William P. Forbes executed the Power of Attorney. |
| 10/19/2025 | Date of transaction for the conversion of restricted stock units into common stock. |
| 10/21/2025 | Date the Form 4 was signed by the Attorney-in-Fact. |
Recommendation
holdThis Form 4 reports a routine vesting and conversion of restricted stock units by an executive. Such transactions are part of standard compensation and do not typically indicate a change in the company's fundamental prospects or warrant a change in investment recommendation. The executive's continued significant beneficial ownership aligns interests with shareholders, supporting a 'hold' position for existing investors.
Keywords
Heron Therapeutics, HRTX, William P. Forbes, Insider Transaction, Form 4, Restricted Stock Units, RSU Conversion, Executive Compensation, Stock Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.